

Appn. No. 10/070,954
Amd. dated July 16, 2007


Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A sulfonamide compound according to formula I



with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar^1 and Ar^2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups with the proviso that Ar^2 is not 1,3-phenylene or 1,4-phenylene,

X is O or S;

R^1 is hydrogen or a C₁-C₆-alkyl group, or R^1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar^1 ;

n is an integer from 0 to 5;

Y within formula I is a substituted or unsubstituted piperidino moiety, whereby one nitrogen atom within said

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007


piperidino moiety forms a bond with the sulfonyl group of formula I thus providing a sulfonamide,

with the proviso that if Ar¹ is 4-chlorophenyl, then X is O, R¹ is H, Ar² is thienyl, and Y is not para-substituted by 2-hydroxyethyl,

with the further proviso that if Ar¹ is phenyl, then X is O, R¹ is H, Ar² is thienyl, and Y is not substituted in its β position by a benzo [5,6] cyclohepta [1,2b] pyridine or a benzo [5,6] cyclohept [3,4]ene [1,2b] pyridine;—unit

with the final proviso that if X is oxygen, then Y shall not be substituted by a group (C=O)N(R,R') at the α-position of the sulfonamide nitrogen.

2. (Currently Amended) A composition for treatment of disorders associated with the abnormal expression or activity of JNK comprising a sulfonamide compound according to formula I



with its geometrical isomers, in an optically active form as enantiomers, dia-stereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar¹ and Ar² are independently from each other substituted or unsubstituted aryl or heteroaryl groups with the proviso that neither A³-Ar¹ nor A²-Ar² is 1,3-phenylene or 1,4-phenylene and Ar¹ is not quinazoline that is substituted by nitro, hydroxyl, or 3,4-dichlorophenyl amino,

X is O or S;

R¹ is hydrogen or a C₁-C₆-alkyl group, or R¹ forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar¹;


n is an integer from 0 to 5;

Y within formula I is a piperidino group whereby one nitrogen atom within said piperidino group forms a bond with the sulfonyl group of formula I thus providing a sulfonamide;

with the proviso that if Y is substituted at the β-position of the piperidino- nitrogen by a benzo[5, 6]cyclohepta[1, 2b]pyridine, or a benzo[5, 6]cyclohept [3, 4]ene [1, 2b]pyridine, while Ar² is thienyl, X is oxygen, R¹ is hydrogen and n is 1, Ar¹ shall not be a phenyl group;

and a pharmaceutically acceptable carrier with the final proviso that if X is oxygen, Y shall not be substituted by a group (C=O)N(R,R') at the α-position of the sulfonamide nitrogen.

3. (Currently Amended) A sulfonamide compound according to claim 1 or a composition according to claim 2, wherein Y is a piperidino group of the formula



whereby, L^1 and L^2 are independently selected from each other from the group consisting of H, substituted or unsubstituted C_1-C_6 -alkyl, substituted or unsubstituted C_2-C_6 -alkenyl, substituted or unsubstituted C_2-C_6 -alkynyl, substituted or unsubstituted cyclic C_4-C_8 -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or L^1 and L^2 are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- C_1-C_6 -alkyl, heteroaryl- C_1-C_6 -alkyl, $-C(O)-OR^3$, $-C(O)-R^3$, $-C(O)-NR^{3'}R^3$, $-NR^{3'}R^3$, $-NR^{3'}C(O)R^3$, $\underline{-NR^{3'}C(O)NR^{3'}R^3-NR^{3'}C(O)NR^{3'}R^3}$, $-(SO)R^3$, $-(SO_2)R^3$, $-NHSO_2R^3$, and $-SO_2NR^{3'}R^3$,

with R³ and R^{3'} being substituents independently selected from the group consisting of H, substituted or unsubstituted C₁-C₆-alkyl, substituted or unsubstituted C₂-C₆-alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-C₁-

Appln. No. 10/070,954
Amd. dated July 16, 2007
Reply to Office Action of January 18, 2007
Advisory Actions of May 2, May 30, and June 26, 2007

C₆-alkyl and substituted or unsubstituted heteroaryl-C₁-C₆-alkyl;

said aryl or heteroaryl groups being optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, amino, acylamino, aminocarbonyl, C₁-C₆-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, and C₁-C₆-thioalkoxy, and

R⁶ is selected from the group consisting of hydrogen, substituted or unsubstituted C₁-C₆-alkyl, substituted or unsubstituted C₁-C₆-alkoxy, OH, halogen, nitro, cyano, sulfonyl and oxo (=O), and

n' is an integer from 0 to 4.

Claim 4. (Cancelled)


5. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar¹ and Ar² are independently selected from the group consisting of phenyl, thienyl, furyl, pyridyl, and optionally substituted by C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, amino, acylamino, aminocarbonyl, C₁-C₆-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl and C₁-C₆-thioalkoxy.

6. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar¹ is an unsubstituted or substituted phenyl.

7. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar² is an unsubstituted or substituted thienyl or furanyl group.

8. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar¹ is selected from the group consisting of a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4,-dihydroxyphenyl, thioxo-dihydropyridine or its tautomer and pyrazole and X is O, R¹ is hydrogen, n is 1, Ar² is thienyl or furanyl.

9. (Currently Amended) A sulfonamide compound according to claim 8, wherein Y is



(R⁶)_{n'} is selected from the group consisting of hydrogen, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted C₁-C₆ alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo; n' is an integer of from 0 to 4; and

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

wherein L¹ and L² are independently selected from each other from the group consisting of H, substituted or unsubstituted C₁-C₆- alkyl, substituted or unsubstituted C₂-C₆ alkenyl; or L¹ and L² are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl-C₁-C₄ alkyl, heteroaryl-C₁-C₄ alkyl, -C(O)-OR³, -C(O)-R³, -C(O)-NR^{3'}R³, -NR^{3'}R³; ~~-NR^{3'}C(O)R³-~~ NR^{3'}C(O)R^{3'}, ~~-NR^{3'}-C(O)NR^{3'}R³-NR^{3'}-C(O)NR³R³,~~ -(SO)R³, -(SO₂)R³, -NHSO₂R³, and -SO₂NR³R^{3'};

with R³ and R^{3'} being substituents independently selected from the group consisting of H, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₂-C₆ alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-C₁-C₄-alkyl, substituted or unsubstituted heteroaryl-C₁-C₆-alkyl;

said aryl or heteroaryl groups being optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, amino, acylamino, aminocarbonyl, C₁-C₆-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, C₁-C₆-thioalkoxy or;

L¹ is a triazole ring fused with an unsubstituted or substituted aryl ring.


Appln. No. 10/070,954
Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

10. (Currently Amended) A sulfonamide compound according to claim 9, wherein R⁶ is H, L² is H, L¹ is a 5-membered cyclic group containing 3 heteroatoms; or L¹ is -C(O)-R³, or -NHR³;

wherein Y is



n' is an integer of from 0 to 4;
with R³ being a substituent selected from the group comprising or consisting of C₁-C₄-alkyl, aryl, heteroaryl, aryl-C₁-C₄-alkyl and heteroaryl-C₁-C₆-alkyl;
said aryl or heteroaryl groups being optionally substituted by halogen, hydroxy, nitro, or sulfonyl.

11. (Currently Amended) A sulfonamide compound according to claim 1, selected from the group consisting of:
4-chloro-N-[5-[4-(3-trifluoromethanesulfonyl-phenylamino)-piperidine-1-sulfonyl]-thiophen-2-ylmethyl]-benzamide;

4-chloro-N-[(5-{[4-(4-fluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-piperidin-1-ylpropyl)piperazin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-({5-[(4-hydroxy-4-phenylpiperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;

N-({5-[(4-benzoylpiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide;

4-chloro-N-[(5-{ [4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[(4-benzylpiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide;

4-chloro-N-[(5-{ [4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

tert-butyl 1-[(5-{ [(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-ylcarbamate;

4-chloro-N-{ [5-(piperidin-1-ylsulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-{ [5-({3-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[(5-{ [4-(benzyloxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N-(4-chlorophenyl)-2-(5-{ [4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)acetamide;

Appn. No. 10/070,954
Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-({5-[(4-hydroxypiperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;
N-({5-[(4-benzyl-4-hydroxypiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide;
N-{ [5-({4-[(2-tert-butyl-1H-indol-5-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl}methyl}-4-chlorobenzamide;
4-chloro-N-{ [5-({4-[(phenylacetyl)amino]piperidin-1-yl}sulfonyl)thien-2-yl}methyl)benzamide;
N-[(5-{ [4-(2H-1,2,3-benzotriazol-2-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
4-chloro-N-[(5-{ [4-(4-chlorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
4-chloro-N-({5-[(4-phenoxy)piperidin-1-yl}sulfonyl]thien-2-yl}methyl)benzamide;
N-{ [5-({4-[benzyl(methyl)amino]piperidin-1-yl}sulfonyl)thien-2-yl}methyl}-4-chlorobenzamide;
4-chloro-N-{ [5-({4-[3-(2,4-dichlorophenyl)-1H-pyrazol-5-yl)piperidin-1-yl}sulfonyl)thien-2-yl}methyl)benzamide;
4-chloro-N-[(5-{ [4-(5-thien-2-yl-1H-pyrazol-3-yl)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-[(5-{ [4-(2,3,4,5,6-pentamethylbenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[5-({4-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}sulfonyl)thien-2-yl]methyl]benzamide;

N- ({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide;

4-chloro-N-[(5-{ [4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N- [(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

2-(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)-N-(4-chlorophenyl)acetamide;

2-{1-[(5-{ [(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylic acid;

4-chloro-N-[(5-{ [4-(5-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

methyl 1-{1-[(5-{ [(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylate;

methyl 1-{1-[(5-{ [(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylate;

methyl 2-[1-[5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl]sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylate;

4-chloro-N-[(5-{[4-(6-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[5-(trifluoromethyl)-1H-1,2,3-benzotriazol-1-yl]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[(5-{[4-(7-aza-1H-benzimidazol-1-yl)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

1-[1-[5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl]sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylic acid;

1-[1-[5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl]sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylic acid;

N-[(5-{[4-(2-amino-9H-purin-9-yl)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(9H-purin-9-yl)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

N-[(5-{[4-(6-amino-9H-purin-9-yl)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-((5-[(4-{6-nitro-1H-benzimidazol-1-yl)piperidin-1-yl}sulfonyl)thien-2-yl)methyl)benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-({5-[(4-{5-nitro-1H-benzimidazol-1-yl}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;

4-chloro-N-[(5-{ [4-(2H-1,2,3-triazol-2-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{ [4-(1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{ [5-({4-[3-propylanilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-{ [5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-{ [5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

methyl 3-({1-[(5-{ [(4-chlorobenzoyl)amino]-methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino)-benzoate;

4-chloro-N-{ [5-({4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-({5-[(4-{3-nitroanilino}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;

4-chloro-N-[(5-{ [4-(2-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

3-({1-[{5-[{(4-chlorobenzoyl)amino]methyl}thien-2-yl]sulfonyl}piperidin-4-yl}amino)benzamide;

4-chloro-N-{[5-({4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-({5-[(4-{2-nitro-4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-{[5-({4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-({5-[(4-{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-{[4-(2-nitroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N- [(5-{[4-(3-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

4-chloro-N- [(5-{[4-(3-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N- [(5-{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N- {[5-({4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N- ({5-[(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-4-chlorobenzamide;

4-chloro-N- ({5-[(4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N- [(5-{[4-(2-aminoanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N- [(5-{[4-(2-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N- [(5-{[4-(4-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N- {[5-[(4-{3-[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-[(5-{ [4-(3-toluidino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[{5-[(4-{ [3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[{5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{ [4-(3-tert-butyylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{ [4-(2-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[{5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino}piperidin-1-yl}sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{ [4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl}sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{ [4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{ [4-({3-nitropyridin-2-yl}amino)piperidin-1-yl}sulfonyl}thien-2-yl)methyl]benzamide;

N-{ [5-({4-[(3-aminopyridin-2-yl)amino}piperidin-1-yl}sulfonyl}thien-2-yl)methyl}-4-chlorobenzamide;

N- [(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N- [(5-{[4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N- [(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N- {[5-({4-[4-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N- ({5-[(4-{[4-(trifluoromethyl)pyrimidin-2-yl]amino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N- [(5-{[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N- ({5-[(4-{3-[butylamino]sulfonyl}anilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;

4-chloro-N- [(5-{[4-(3-ethylanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N- [(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

N- {[5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-4-chlorobenzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-[(5-{ [4-(quinolin-5-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{ [4-(quinolin-8-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-Chloro-N-[(5-{ [4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl)benzamide;

N-[(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

4-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl)benzamide;

N-[(5-{ [4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

N-[(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

N-[(5-{ [4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

4-nitro-N-({5-[(4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl)methyl)benzamide;

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

N- [(5-{[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

N- [(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

3-nitro-N- [(5-{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-nitro-N- { [5- ({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N- { [5- ({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;

3-nitro-N- { [5- ({4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

3-nitro-N- { [5- ({4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N- { [5- ({4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;

methyl 3- { [1- ({5- [{3-nitrobenzoyl}amino]methyl}-thien-2-yl}sulfonyl)-piperidin-4-yl]amino}benzoate;

N- { [5- ({4-[3-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

3-nitro-N- ({ 5- [(4- { 3-nitroanilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) benzamide;

3-nitro-N- [(5- { [4- (2-methoxyanilino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;

3-nitro-N- { [5- ({ 4- [2- (trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) thien-2-yl] methyl} benzamide;

3-nitro-N- ({ 5- [(4- { 2-nitroanilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) benzamide;

N- [(5- { [4- (4-chloroanilino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -3-nitrobenzamide;

3-nitro-N- { [5- ({ 4- [4- (trifluoromethyl) anilino] piperidin-1-yl} sulfonyl) thien-2-yl] methyl} benzamide;

3-nitro-N- ({ 5- [(4- { 4- [(trifluoromethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) benzamide;

N- { [5- ({ 4- [4- (aminocarbonyl) anilino] piperidin-1-yl} sulfonyl) thien-2-yl] methyl} -3-nitrobenzamide;

N- [(5- { [4- (3-propylanilino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -3-nitrobenzamide;

N- [(5- { [4- (3-chloroanilino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] -4-nitrobenzamide;

Appn. No. 10/070,954
Amd. dated July 16, 2007
Reply to Office Action of January 18, 2007
Advisory Actions of May 2, May 30, and June 26, 2007

4-nitro-N-[(5-[{4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-{[5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

4-nitro-N-[(5-[{4-(3-propylanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

4-nitro-N-{[5-({4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-nitro-N-{[5-({4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-{[5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

methyl 3-[(1-[(5-[(4-nitrobenzoyl)amino]methyl)thien-2-yl]sulfonyl)piperidin-4-yl]amino}benzoate;

3-[(1-[(5-[(4-nitrobenzoyl)amino]methyl)thien-2-yl]sulfonyl)piperidin-4-yl]amino}benzamide;

4-nitro-N-[(5-[(4-(3-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-nitro-N-[(5-{ [4-(2-methoxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[5-{ {4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl}thien-2-yl]methyl]benzamide;

4-nitro-N-[{5-[(4-{2-nitroanilino}piperidin-1-yl)sulfonyl}thien-2-yl]methyl]benzamide;

N-[(5-{ [4-(4-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;

4-nitro-N-[5-{ {4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl}thien-2-yl]methyl]benzamide;

4-nitro-N-[{5-[(4-{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl]methyl]benzamide;

N-[5-{ {4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl}thien-2-yl]methyl]-4-nitrobenzamide;

N-[5-{ {4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl}thien-2-yl]methyl]-4-nitrobenzamide;

N-[{5-[(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl]methyl]-3-nitrobenzamide;

N-[{5-[(4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl}thien-2-yl]methyl]-3-nitrobenzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

N- ({5- [(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-3-nitrobenzamide;

N- ({5- [(4-{3- [(2-hydroxyethyl)sulfonyl]anilino)piperidin-1-yl}sulfonyl]thien-2-yl}methyl)-4-nitrobenzamide;

N- ({5- [(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-4-nitrobenzamide;

N- ({5- [(4-{3- [amino(imino)methyl]anilino)piperidin-1-yl}sulfonyl]thien-2-yl}methyl)-4-nitrobenzamide;

3-nitro-N- ({5- [(4-{3- [(trifluoromethyl)sulfanyl]anilino)piperidin-1-yl}sulfonyl]thien-2-yl}methyl)benzamide;

4-nitro-N- ({5- [(4-{3- [(trifluoromethyl)sulfanyl]anilino)piperidin-1-yl}sulfonyl]thien-2-yl}methyl)benzamide;

3-nitro-N- [(5- {[4- ({3-nitropyridin-2-yl}amino)piperidin-1-yl}sulfonyl]thien-2-yl}methyl)benzamide;

N- {[5- ({4- [(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl}methyl}-3-nitrobenzamide;

N- [(5- {[4- (2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl}sulfonyl]thien-2-yl}methyl]-3-nitrobenzamide;

3-nitro-N- [(5- {[4- (2-propylanilino)piperidin-1-yl}sulfonyl]thien-2-yl}methyl)benzamide;

Appn. No. 10/070,954
Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007
Advisory Actions of May 2, May 30, and June 26, 2007

3-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-[3-(1,3-oxazol-5-yl)anilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-((5-[(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-nitrobenzamide;

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-[(5-{[4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-[3-(morpholin-4-ylsulfonyl)anilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-nitro-N-[(5-{[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

N- { [5- ({ 4- [(3-aminopyridin-2-yl)amino]piperidin-1-
yl} sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

4-nitro-N- [(5- { [4- ({ 3-nitropyridin-2-
yl} amino)piperidin-1-yl] sulfonyl)thien-2-yl]methyl]benzamide;

N- [(5- { [4- (2,3-dihydro-1H-inden-5-ylamino)piperidin-
1-yl] sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

4-nitro-N- [(5- { [4- (2-propylanilino)piperidin-1-
yl] sulfonyl)thien-2-yl]methyl]benzamide;

4-nitro-N- [(5- { [4- (4-propylanilino)piperidin-1-
yl] sulfonyl)thien-2-yl]methyl]benzamide;

N- [(5- { [4- (3-tert-butyylanilino)piperidin-1-
yl] sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

4-nitro-N- { [5- ({ 4- [3- (1,3-oxazol-5-
yl)anilino]piperidin-1-yl} sulfonyl)thien-2-
yl]methyl}benzamide;

4-nitro-N- [(5- { [4- (2-phenylethyl)piperidin-1-
yl] sulfonyl)thien-2-yl]methyl]benzamide;

N- ({ 5- [(4- {[3-chloro-5- (trifluoromethyl)pyridin-2-
yl]amino}piperidin-1-yl) sulfonyl]thien-2-yl}methyl)-4-
nitrobenzamide;

N- [(5- { [4- ([1,1'-biphenyl]-3-ylamino)piperidin-1-
yl] sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

N- [(5- { [4- (3-benzylanilino)piperidin-1-
yl] sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;

Appn. No. 10/070,954
Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-nitro-N-{[5-({4-[3-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[(5-{[4-(2-aminoanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

N-({5-[(4-{2-nitro-4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

3-nitro-N-({5-[(4-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

N-({5-[(4-{3-[(butylamino)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

N-[(5-{[4-(3-ethylanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-nitro-N-[(5-[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

N-[(5-[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

N-[(5-[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-3-methoxybenzamide;

2-Hydroxy-N-({5-[(4-{3-[trifluoromethyl}sulfonyl]anilino)piperidin-1-yl]sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-3-methoxybenzamide;

N-[(5-[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-2-hydroxybenzamide;

N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

3-methoxy-N-[(5-[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

3-methoxy-N-{{5-({4-[3-(trifluoromethyl)anilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-{{5-({4-[3-(dimethylamino)anilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-methoxybenzamide;

3-methoxy-N-[(5-[4-(3-propylanilino)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated July 16, 2007
Reply to Office Action of January 18, 2007
Advisory Actions of May 2, May 30, and June 26, 2007

3-methoxy-N-[5-(4-[3-(methylsulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}benzamide;

3-methoxy-N-[5-(4-[3-(methylsulfanyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}benzamide;

N-[5-(4-[3-(aminosulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}-3-methoxybenzamide;

methyl 3-[(1-[(5-[(3-methoxybenzoyl)amino]-methyl)thien-2-yl)sulfonyl]piperidin-4-yl)amino]-benzoate;

N-[5-(4-[3-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}-3-methoxybenzamide;

3-methoxy-N-[(5-[(4-(2-methoxyanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-[(5-[(4-(3-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-[5-(4-[2-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}benzamide;

N-[(5-[(4-(2-nitroanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

N-[5-(4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}-3-methoxybenzamide;

Appn. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

N- { [5- ({4- [4- (1,3-dithiolan-2-yl) anilino] piperidin-1-yl} sulfonyl) thien-2-yl] methyl } -3-methoxybenzamide;

N- [(5- { [4- (3-chloroanilino) piperidin-1-yl] sulfonyl } thien-2-yl] methyl] -3-methoxybenzamide;

N- [(5- { [4- (4-chloroanilino) piperidin-1-yl] sulfonyl } thien-2-yl] methyl] -3-methoxybenzamide;

3-methoxy-N- ({5- [(4- {4- [(trifluoromethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl } thien-2-yl] methyl) benzamide;

N- ({5- [(4- {3- [amino (imino) methyl] anilino} piperidin-1-yl) sulfonyl } thien-2-yl] methyl) -3-methoxybenzamide;

N- ({5- [(4- {3- [(2-hydroxyethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl } thien-2-yl] methyl) -3-methoxybenzamide;

3-methoxy-N- ({5- [(4- {3- [(trifluoromethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl } thien-2-yl] methyl) benzamide;

N- ({5- [(4-anilinopiperidin-1-yl) sulfonyl } thien-2-yl] methyl) -3-methoxybenzamide;

3-methoxy-N- ({5- [(4- {3- [(trifluoromethyl) sulfanyl] anilino} piperidin-1-yl) sulfonyl } thien-2-yl] methyl) benzamide;

N- [(5- { [4- (4-hydroxyanilino) piperidin-1-yl] sulfonyl } thien-2-yl] methyl] -3-methoxybenzamide;

3-nitro-N- ({ 5- [(4- { 3-
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-
yl) sulfonyl]thien-2-yl}methyl)benzamide;

4-nitro-N- ({ 5- [(4- { 3-
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-
yl) sulfonyl]thien-2-yl}methyl)benzamide;

N- [(5- { [4- (2-hydroxyanilino)piperidin-1-
yl] sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- [(5- { [4- (pyrimidin-2-ylamino)piperidin-1-
yl] sulfonyl]thien-2-yl)methyl]benzamide;

N- { [5- ({ 4- [(3-aminopyridin-2-yl)amino]piperidin-1-
yl} sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

N- [(5- { [4- ({ 3-nitropyridin-2-yl}amino)piperidin-1-
yl] sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

N- { [5- ({ 4- [(2,2-dioxido-1,3-dihydro-2-benzothien-5-
yl)amino]piperidin-1-yl} sulfonyl]thien-2-yl)methyl}-3-
methoxybenzamide;

N- [(5- { [4- (2,3-dihydro-1H-inden-5-ylamino)piperidin-1-
yl] sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- [(5- { [4- (2-propylanilino)piperidin-1-
yl] sulfonyl]thien-2-yl)methyl]benzamide;

3-methoxy-N- [(5- { [4- (4-propylanilino)piperidin-1-
yl] sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

N- [(5- { [4- (3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N- ({5- [(4- {[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-methoxybenzamide;

3-methoxy-N- {[5- ({4- [3- (1,3-oxazol-5-yl)anilino]}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N- [(5- { [4- ([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- [(5- {[4- (3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

3-methoxy-N- {[5- ({4- [3- (morpholin-4-ylsulfonyl)anilino]}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

3-methoxy-N- [(5- {[4- (2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N- [(5- {[4- (3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- ({5- [(4- {[4- (trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N- [(5- {[4- (3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

N- ({5- [(4-{3-

[(butylamino)sulfonyl]anilino)piperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-3-methoxybenzamide;

N- [(5-{[4-(3-ethylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- [(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-
ylamino)piperidin-1-yl)sulfonyl}thien-2-yl)methyl]benzamide;

N- [(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-5-nitro-1H-pyrazole-3-
carboxamide;

N- [(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-2-oxo-1,2-dihydropyridine-3-
carboxamide;

N- [(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-2-thioxo-1,2-dihydropyridine-3-
carboxamide;

N- [(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3,4-dihydroxybenzamide;

N- [(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]pyridine-2-carboxamide;

N- [(5-{[4-(hexyloxy)piperidin-1-yl)sulfonyl}thien-2-
yl)methyl]-3-methoxybenzamide;

N- ({5- [(4-heptanoylpiperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-3-methoxybenzamide;

Appn. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-[(5-{ [4-(3-propylanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[(5-{ [4-(3-chloroanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[(5-{ [4-(3-methoxyanilino)piperidin-1-yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-[5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl]benzamide;

4-chloro-N-[5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl]benzamide;

4-chloro-N-[5-({4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl]benzamide;

4-chloro-N-[5-({4-[3-(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl]benzamide;

N-[5-({4-[3-(aminosulfonyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl]-4-chlorobenzamide;

methyl 3-([1-[(5-{ [(4-chlorobenzoyl)amino]methyl}-2-furyl)sulfonyl]piperidin-4-yl]amino)benzoate;

3-([1-[(5-{ [(4-chlorobenzoyl)amino]methyl}-2-furyl)sulfonyl]piperidin-4-yl]amino)benzamide;

Appln. No. 10/070,954
Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

4-chloro-N-({5-[{4-{3-nitroanilino}piperidin-1-yl]sulfonyl}-2-furyl}methyl)benzamide;

4-chloro-N-[{5-[{4-(2-methoxyanilino)piperidin-1-yl]sulfonyl}-2-furyl}methyl]benzamide;

4-chloro-N-[{5-[{4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]-2-furyl}methyl]benzamide;

4-chloro-N-({5-[{4-{2-nitroanilino}piperidin-1-yl]sulfonyl}-2-furyl}methyl)benzamide;

4-chloro-N-[{5-[{4-(4-chloroanilino)piperidin-1-yl]sulfonyl}-2-furyl}methyl]benzamide;

4-chloro-N-[{5-[{4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]-2-furyl}methyl]benzamide;

4-chloro-N-({5-[{4-[{4-(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl}sulfonyl]-2-furyl}methyl)benzamide;

N-[{5-[{4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl]-2-furyl}methyl]-4-chlorobenzamide;

4-chloro-N-[{5-[{4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl]-2-furyl}methyl]benzamide;

N-({5-[{4-{3-[amino(imino)methyl]anilino}piperidin-1-yl}sulfonyl]-2-furyl}methyl)-4-chlorobenzamide;

4-chloro-N-({5-[{4-{3-[
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-
furyl}methyl)benzamide;

N-({5-[{4-anilinopiperidin-1-yl)sulfonyl]-2-
furyl}methyl)-4-chlorobenzamide; and

4-nitro-N-({5-[{4-{3-[
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl)sulfonyl]-2-
furyl}methyl)benzamide.

12. (Previously Presented) A sulfonamide compound according to claim 11, which is selected from the group consisting of:

4-chloro-N-[(5-[{4-(2,4-difluorobenzoyl)piperidin-1-
yl)sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[{4-anilinopiperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-4-chlorobenzamide;

N-[(5-[{4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

N-[(5-[{4-(1H-benzimidazol-1-yl)piperidin-1-
yl)sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{{5-[{4-[3-propylanilino}piperidin-1-
yl)sulfonyl}thien-2-yl)methyl}benzamide;

4-chloro-N-[(5-[{4-(4-chloroanilino)piperidin-1-
yl)sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated July 16, 2007
Reply to Office Action of January 18, 2007
Advisory Actions of May 2, May 30, and June 26, 2007


4-chloro-N-((5-[(4-[3-[(2-
hydroxyethyl)sulfonyl]anilino)piperidin-1-yl)sulfonyl]thien-2-
yl)methyl)benzamide;
N-((5-((4-[3-(aminosulfonyl)anilino)piperidin-1-
yl)sulfonyl)thien-2-yl)methyl)-4-chlorobenzamide;
4-nitro-N-((5-((4-(3-methoxyanilino)piperidin-1-
yl)sulfonyl)thien-2-yl)methyl)benzamide;
methyl 3-((1-((5-((4-
nitrobenzoyl)amino)methyl)thien-2-yl)sulfonyl)piperidin-4-
yl)amino}benzoate;
N-((5-((4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl)thien-2-yl)methyl)-2-hydroxybenzamide; and
N-((5-((4-(2-nitroanilino)piperidin-1-
yl)sulfonyl)thien-2-yl)methyl)-3-methoxybenzamide.

Claims 13-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition containing at least one sulfonamide compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.


21. (Previously Presented) Process for the preparation of a sulfonamide compound according to claim 1, comprising reacting a sulfonyl chloride V

Appln. No. 10/070,954
 Amd. dated July 16, 2007
 Reply to Office Action of January 18, 2007
 Advisory Actions of May 2, May 30, and June 26, 2007



V


with an amine VIII



VIII


whereby $(\text{R}^6)_n$, L^1 and L^2 are as defined in claim 1.

22. . (Previously Presented) A process according to claim 21, wherein said sulfonyl chloride V is obtained by
 a) coupling an amine of formula II:




II

with an acyl chloride of formula III:




III

to provide an amide of formula IV:



IV

b) sulfonating the amide of formula IV to provide a sulfonyl chloride V



V.

Claims 23-26. (Cancelled)

27. (Previously Presented) The sulfonamide compound according to claim 1 wherein n is an integer of from 1 to 3.

28. (Previously Presented) The sulfonamide compound according to claim 27 wherein n is 1.

29. (Previously Presented) The composition according to claim 2 wherein n is an integer of from 1 to 3.

30. (Previously Presented) The composition according to claim 29 wherein n is 1.

31. (Previously Presented) The composition according to claim 3 wherein n is 1 or 2.

Claims 32-34. (Cancelled)

35. (Previously Presented) The sulfonamide compound according to claim 5 wherein the C₁-C₆ alkyl group is trihalomethyl.

Appln. No. 10/070,954

Amd. dated July 16, 2007

Reply to Office Action of January 18, 2007

Advisory Actions of May 2, May 30, and June 26, 2007

36. (Previously Presented) The sulfonamide compound according to claim 10 wherein L¹ is a triazole ring which is fused with an unsubstituted or substituted aryl ring.

Claims 37-41. (Cancelled)